Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
GeoVax Labs, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
GOVX
Nasdaq
2830
www.geovax.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for GeoVax Labs, Inc.
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
- Feb 11th, 2025 2:00 pm
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
- Feb 5th, 2025 2:00 pm
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
- Feb 4th, 2025 2:00 pm
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
- Feb 3rd, 2025 2:00 pm
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
- Jan 29th, 2025 2:00 pm
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
- Jan 27th, 2025 2:00 pm
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
- Jan 15th, 2025 2:00 pm
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now
- Jan 15th, 2025 12:00 pm
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
- Jan 13th, 2025 2:00 pm
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
- Jan 8th, 2025 2:00 pm
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
- Jan 6th, 2025 2:00 pm
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
- Dec 9th, 2024 2:00 pm
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
- Nov 26th, 2024 2:00 pm
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
- Nov 19th, 2024 2:00 pm
Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges
- Nov 13th, 2024 7:16 am
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
- Nov 12th, 2024 9:00 pm
GeoVax Labs initiated with a Buy at Alliance Global Partners
- Nov 12th, 2024 12:07 pm
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
- Nov 5th, 2024 2:00 pm
Geovax Labs Inc (GOVX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
- Oct 9th, 2024 9:07 pm
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
- Oct 2nd, 2024 1:00 pm
Scroll